|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02162 KEYMED BIO-B
Nominal 
77.750 +0.700 (+0.909%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 617,068 | 23.722% | 716,313 | 428,124 | 354,095 | 100,063 |
| Cost of Sales | (118,743) | 254.711% | (88,048) | (12,200) | (36,878) | (2,585) |
| Gross Profit | 498,325 | 7.103% | 628,265 | 415,924 | 317,217 | 97,478 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (401) | -29.152% | (674) | (5,256) | (4,748) | (9,711) | |
| Profit / (Loss) before Taxation | 1,507,767 | -- | (520,723) | (508,647) | (356,188) | (303,597) | |
| Taxation | (290,154) | 9155.311% | (1,874) | (6,260) | (1,597) | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (166) | 277.273% | (44) | (334) | (1,572) | (4,518) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,217,447 | -- | (522,641) | (515,241) | (359,357) | (308,115) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (16,564) | -48.884% | (53,277) | (69,869) | (71,087) | (45,919) |
| Depreciation & Amortisation | 42,689 | -12.675% | 98,027 | 93,228 | 69,161 | 36,123 |
| Directors' Emoluments | -- | -- | -- | 11,191 | 11,143 | 10,208 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 429.000 | -- | -191.000 | -197.000 | -137.000 | -118.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (2.600) | (3.014) | (1.162) | (1.539) |
| NBV per share ($) | 13.409 | -- | 9.287 | 8.846 | 10.675 | 11.941 |
| Remarks: | Real time quote last updated: 20/08/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,217,447 |
| %Change | -- |
| EPS / (LPS) | RMB 4.290 |
| NBV Per Share (¥) | RMB 13.409 |